Planned Cycle Reservation in Repeated ¹⁷⁷Lu-PSMA Treatment in Relapsing mCRPC: Lessons from the first Rechallenge in Greece (EANM 2026) - Sep 29, 2026 - Abstract #EP-1322; "This case highlights both the potential and limitations of lutetium-PSMA rechallenge in mCRPC. Retreatment with 177Lu-PSMA-617, successfully induced a second significant remission, supporting the feasibility of sequential PSMA-targeted radioligand therapy. However, rapid relapse four months after the fourth retreatment cycle, followed by complete PSA non-response to two reserved cycles, underscores a critical limitation of planned cycle reservation: disease biology can shift rapidly, rendering deferred therapy ineffective."
Castration-Resistant Prostate Cancer • Prostate Cancer
|
|
J. Koutsikos 1, 2; S. Bacalis 2; A. Kokkini - Paschou 2; G. Papadopoulos 1
|